What does PHARMASOVA do?

PHARMASOVA is registered with the CBE as active in: Activiteiten van holdings. Public Limited, started on 30 June 2003.

What is the address of PHARMASOVA?

The registered office of PHARMASOVA is located at René Berrewaertslaan 16, 1070 Anderlecht.

Is PHARMASOVA still active?

Yes. According to the CBE (31 October 2026) PHARMASOVA is active, legal situation “Normale toestand”, started on 30 June 2003.

Is PHARMASOVA registered on Peppol?

Yes, PHARMASOVA is registered on the Peppol network with ID 0208:0864058578.

What is the enterprise number of PHARMASOVA?

The enterprise number of PHARMASOVA is BE0864058578.

When was PHARMASOVA founded?

PHARMASOVA was founded on 30 June 2003.

Who are the directors of PHARMASOVA?

According to the 2025 annual accounts, the directors of PHARMASOVA are: Rita LABIS, Daniel CATOUL, E2A SRL.

Is PHARMASOVA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 June 2003; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PHARMASOVA make in 2025?

PHARMASOVA posted a profit after taxes of € 1,851,843 in financial year 2025.

What is the revenue of PHARMASOVA?

As a small company, PHARMASOVA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 82,828.

PHARMASOVA (Public Limited) - Anderlecht - BE0864058578

Dossier PHARMASOVA, printed on 31 October 2026 from databakkes.be/en/0864058578/pharmasova. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMASOVA from Anderlecht, company number BE0864058578, closed financial year 2025 with a result of € 1.9 million after tax. For that financial year PHARMASOVA recorded a gross margin of € 82,828 and equity of € 27.9 million. Compared with financial year 2024, the result moved from € 1.5 million to € 1.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 27.9 million

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 1.9 million

▲ 25% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 89,797

▼ 48% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1.8 million paid out

95 % of the profit went to the shareholders, mostly to E2A Partners (95 % of the shares). That is where the money ends up.

Debts at end 2025

Bank debt

€ 8.1 million

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 2,980

▼ 21% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 9,475

▲ 44% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 101,468 Gross margin 2022: € 101,468 First fiscal year in the series	€ 83,715 Gross margin 2023: € 83,715 ▼ 17% vs 2022 (€ 101,468) Unfavourable step	€ 92,829 Gross margin 2024: € 92,829 ▲ 11% vs 2023 (€ 83,715) Favourable step	€ 82,828 Gross margin 2025: € 82,828 ▼ 11% vs 2024 (€ 92,829) Unfavourable step	▼ 11%
Profit after taxes	€ 3,930,778 Profit after taxes 2022: € 3,930,778 First fiscal year in the series	€ 362,997 Profit after taxes 2023: € 362,997 ▼ 91% vs 2022 (€ 3,930,778) Unfavourable step	€ 1,481,017 Profit after taxes 2024: € 1,481,017 ▲ € 1.1 million vs 2023 (€ 362,997) Favourable step	€ 1,851,843 Profit after taxes 2025: € 1,851,843 ▲ 25% vs 2024 (€ 1,481,017) Favourable step	▲ 25%
Equity	€ 27,726,912 Equity 2022: € 27,726,912 First fiscal year in the series	€ 27,747,709 Equity 2023: € 27,747,709 Unchanged (€ 27,726,912) Favourable step	€ 27,828,726 Equity 2024: € 27,828,726 Unchanged (€ 27,747,709) Favourable step	€ 27,928,969 Equity 2025: € 27,928,969 Unchanged (€ 27,828,726) Favourable step
Total debts	€ 12,792,883 Total debts 2022: € 12,792,883 First fiscal year in the series	€ 12,674,845 Total debts 2023: € 12,674,845 ▼ 1% vs 2022 (€ 12,792,883) Favourable step	€ 11,221,441 Total debts 2024: € 11,221,441 ▼ 11% vs 2023 (€ 12,674,845) Favourable step	€ 10,992,755 Total debts 2025: € 10,992,755 ▼ 2% vs 2024 (€ 11,221,441) Favourable step	▼ 2%
Cash	€ 842,150 Cash 2022: € 842,150 First fiscal year in the series	€ 175,268 Cash 2023: € 175,268 ▼ 79% vs 2022 (€ 842,150) Unfavourable step	€ 173,966 Cash 2024: € 173,966 ▼ 1% vs 2023 (€ 175,268) Unfavourable step	€ 89,797 Cash 2025: € 89,797 ▼ 48% vs 2024 (€ 173,966) Unfavourable step	▼ 48%
Retained profit	€ 21,389,603 Retained profit 2022: € 21,389,603 First fiscal year in the series	€ 21,410,400 Retained profit 2023: € 21,410,400 Unchanged (€ 21,389,603) Favourable step	€ 21,491,417 Retained profit 2024: € 21,491,417 Unchanged (€ 21,410,400) Favourable step	€ 21,591,660 Retained profit 2025: € 21,591,660 Unchanged (€ 21,491,417) Favourable step
Dividend	€ 1,599,000 Dividend 2022: € 1,599,000 First fiscal year in the series	€ 342,200 Dividend 2023: € 342,200 ▼ 79% vs 2022 (€ 1,599,000) Unchanged	€ 1,400,000 Dividend 2024: € 1,400,000 ▲ € 1.1 million vs 2023 (€ 342,200) Unchanged	€ 1,751,600 Dividend 2025: € 1,751,600 ▲ 25% vs 2024 (€ 1,400,000) Unchanged	▲ 25%
Bank debt	€ 8,085,420 Bank debt 2022: € 8,085,420 First fiscal year in the series	€ 8,085,420 Bank debt 2023: € 8,085,420 Unchanged (€ 8,085,420) Unchanged	€ 8,085,420 Bank debt 2024: € 8,085,420 Unchanged (€ 8,085,420) Unchanged	€ 8,085,420 Bank debt 2025: € 8,085,420 Unchanged (€ 8,085,420) Unchanged
Balance sheet total	€ 40,519,794 Balance sheet total 2022: € 40,519,794 First fiscal year in the series	€ 40,422,554 Balance sheet total 2023: € 40,422,554 Unchanged (€ 40,519,794) Unchanged	€ 39,050,167 Balance sheet total 2024: € 39,050,167 ▼ 3% vs 2023 (€ 40,422,554) Unchanged	€ 38,921,724 Balance sheet total 2025: € 38,921,724 Unchanged (€ 39,050,167) Unchanged

Key figures of PHARMASOVA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to PHARMASOVA?

What happened at PHARMASOVA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: profit of € 1.9 million (▲ 25% vs 2024). Source: NBB ↗
2021 Daniel CATOUL became a director. NBB
2021 E2A SRL became a director. NBB
2021 Rita LABIS became a director. NBB
Jun 30, 2003 Start of the company according to the CBE. KBO

In short

From € 3.9 million profit in 2022 to € 1.9 million profit in 2025.

Paid € 2,158 in corporate taxes since 2022.

Best year ever: 2022, with € 3.9 million profit.

Paid out € 5.1 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

E2A Partners 95%

The stake of E2A Partners comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMASOVA

Laboratoires Belges PHARMACOBEL 100%

STEROP 100%

MEDI-LABO 100%

STEROP OVERSEAS 100%

Behind PHARMASOVA are Rita LABIS, Daniel CATOUL and E2A SRL. The shares are held by E2A Partners (95%). It owns 100% of Laboratoires Belges PHARMACOBEL, 100% of STEROP, 100% of MEDI-LABO and 100% of STEROP OVERSEAS itself.

Directors

According to the 2025 annual accounts

Rita LABIS

Director

Also active at: Etablissements Medi-Labo, Laboratoires Sterop

since 2021

Daniel CATOUL

Director

Also active at: Laboratoires Belges Pharmacobel, Etablissements Medi-Labo, C.D. & ASSOCIES, Leo Keller en Zonen, Laboratoires Sterop, T.DIFFUSION, Sterop Overseas, ALTERNATIV WORKSPACE SOLUTIONS +7 more

since 2021

E2A SRL

Managing director · represented by Sophie EYKERMAN

Also active at: Laboratoires Belges Pharmacobel, Etablissements Medi-Labo, Laboratoires Sterop, Sterop Overseas

since 2021

Shareholders

E2A Partners

95%

Participations

Laboratoires Belges PHARMACOBEL

100%

STEROP

100%

MEDI-LABO

100%

STEROP OVERSEAS

100%

Establishments

Establishment units

Physical locations of this company

Registered office

René Berrewaertslaan 16

1070 Anderlecht

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0864.058.578

VAT number

BE 0864.058.578

Registered office

René Berrewaertslaan 16, 1070 Anderlecht

Names & denominations

PHARMASOVA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

30 June 2003

Peppol

Active · Active since 1 Apr 2026

Activities · NACE

Activiteiten van holdings

Managementactiviteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMASOVA

Financials

What happened to PHARMASOVA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions